Basiliximab: 20 mg, IV (in the vein) on day 1 and 4.
Methylprednisolone: 125 mg, IV (in the vein) on day 1.
Prednisone: 60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
Tacrolimus: 1-5 mg PO, twice a day (BID) days 2-180.
Mycophenolate mofetil: 500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
Colchicine for Amyotrophic Lateral Sclerosis: Colchicine 1 MG Oral Tablet or placebo
AMX0035 for Amyotrophic Lateral Sclerosis:
MCI-186 in open label phase for Amyotrophic Lateral Sclerosis: Double-Blind, Parallel-Group, Placebo-Controlled Manner MCI-186 \cite{2017}
Two ampoules (60 mg) of MCI-186 or placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
Other Names:
A Study for Patients Who Completed VITALITY-ALS (CY 4031) (VIGOR-ALS): tirasemtiv 250-500 mg/day Oral Other Name: CK-2017357 Clinical trial identifier NCT02936635
Ataxin \cite{Becker_2017}
T
DP-43 aggregation was found in more than 90%[9] of patients with sporadic ALS especially who are without mutations in superoxide dismutase-1 (SOD-1) and fused in sarcoma (FUS) genes.[9–12] Polyglutamine Binding Peptide 1 (QBP1):
Acridine imidazolium (AIM4): derivative compound, AIM4 Amandeep GirdharInternational Journal of Biological Macromolecules doi:10.1016/j.ijbiomac.2020.01.032is shown to inhibit the liquid-liquid phase separation that occurs in ALS proteinopathy.
small molecules explain briefly
dna repair explain briefly
localization